news

Cancer Immunotherapy Webinar Series

Long-sought efforts to unleash the immune system against tumors are producing remarkable results in subsets of patients. Scientists expect that immunotherapies will eventually come to dominate many aspects of cancer therapy given the pace of R&D in the field.

APC is proud to support the efforts of the Cancer Research Institute in disseminating state-of-the-art information to raise awareness of the enormous promise of immunotherapy and how it is revolutionizing cancer treatment.

Breakthroughs in Cancer Immunotherapy Webinar Series

View Webinars

Press Releases

Advanced Proteome Therapeutics latest news releases are provided to keep you updated about the company’s activities. To be put on our news release email list please send your name, telephone number and email address to akrantz@advancedproteome.com

February 6, 2017

Advanced Proteome Therapeutics Corporation is pleased to announce the appointment of Dr. Randal Chase to its executive leadership team to help shape the Company’s future and advance its technology and business objectives in the domain of antibody-based therapeutics.


View PDF

January 25, 2017

Advanced Proteome Therapeutics Corporation is pleased to announce that it has closed the third tranche of a non-brokered private placement announced October 25, 2016 by the issuance of 252,000 units at a purchase price of $0.05 per Unit for gross proceeds of $12,600.


View PDF

January 23, 2017

APC announces the grant of incentive stock options to directors, officers, employees and consultants to purchase an aggregate of 1,005,000 common shares in the capital of the Company, exercisable at a price of CDN $0.05 per share for a period of five years.


View PDF

January 17, 2017

Advanced Proteome Therapeutics Corporation is pleased to announce issuance of APC’s U.S. Patent Application 14/400,190 titled “Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”.


View PDF

January 9, 2017

Advanced Proteome Therapeutics Corporation is pleased to announce that it has filed intellectual property to cover methods for site-selective labeling of antibodies and related composition of matter that possess potential commercial value, particularly in the field of medicine and cancer therapies.


View PDF

December 23, 2016

Advanced Proteome Therapeutics Corporation is pleased to announce that it has closed the second tranche of a non-brokered private placement (the “APC Private Placement”) announced October 25, 2016 to raise an aggregate of $600,000 through the issuance of (i) up to 6,000,000 units (“Units”) at $0.05 per Unit and (ii) up to 6,000,000 common shares at $0.05 per share.


View PDF

December 19, 2016

Advanced Proteome Therapeutics Corporation is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for APC’s U.S. Patent Application Serial Number 14/400,190 titled “Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”.


View PDF

November 29, 2016

Advanced Proteome Therapeutics Corporation is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according to the degree of selective labeling resulting from modification of a target antibody for conjugation.


View PDF

November 24, 2016

Advanced Proteome Therapeutics Corporation announces that it has requested and received TSX Venture Exchange approval to extend closing of the second tranche of a non-brokered private placement previously announced October 25, 2016 (the “Private Placement”).


View PDF

November 17, 2016

Advanced Proteome Therapeutics Corporation announces a non-brokered private placement of its wholly-owned subsidiary 1090573 B.C. Ltd. (“PrivCo”) of up to 6,000,000 units (the “Units”) at a price of $0.06 per Unit to raise gross proceeds of up to $300,000 (the "Private Placement").


View PDF

October 31, 2016

Announce that it has closed the first tranche of a non-brokered private placement financing (“Private Placement”) announced October 25, 2016 by the issuance of an aggregate of 2,600,000 units (“Units”) at a purchase price of $0.05 per Unit for gross proceeds of $130,000.


View PDF

October 25, 2016

Advanced Proteome Therapeutics Corporation announces a non-brokered private placement to raise gross proceeds of up to $600,000 (the "Private Placement"), consisting of two parts.


View PDF

October 19, 2016

Advanced Proteome Therapeutics Corporation today announced that it has entered into an exclusive option agreement with the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto (UT).


View PDF

October 7, 2016

Has retained Virtus Advisory Group Inc. (“Virtus”), to develop and implement a strategic corporate communications program to increase the Company’s exposure among industry stakeholders and investors across Canada.


View PDF

June 14, 2016

Heidelberg Pharma GmbH, Ladenburg, Germany, a subsidiary of Wilex AG, entered into a partnership with APC to create a new generation of antibody-drug conjugates (ADCs).


View PDF

May 19, 2016

Closed the non-brokered private placement financing (“Private Placement”) announced April 18, 2016 by the issuance of an aggregate of 5,703,000 units (“Units”) at a purchase price of $0.05 per Unit for gross proceeds of $285,150.


View PDF

April 18, 2016

A non-brokered private placement consisting of up to 6,000,000 units ("Units") at a price of CDN $0.05 per Unit to raise gross proceeds of up to CDN $300,000 (the "Private Placement").


View PDF

March 24, 2016

APC will be attending the 10th Annual International Partnering Conference, at BIO-Europe, Spring 2016, April 4-6, in Stockholm, Sweden. This is Europe's largest partnering conference within the global biotechnology industry.


View PDF

January 4, 2016

Advanced Proteome Therapeutics attending JP Morgan healthcare conference week January 10-14, 2016


View PDF

December 29, 2015

Advanced Proteome Therapeutics grants stock options


View PDF

December 4, 2015

Advanced Proteome Therapeutics announces updates study of APC 101


View PDF

August 5, 2015

Advanced Proteome Therapeutics announces results of annual general meeting


View PDF

June 2, 2015

Advanced Proteome Therapeutics appoints Dr. Randal Chase to its board


View PDF

May 19, 2015

Advanced Proteome Therapeutics reports on warrant exercise


View PDF

April 29, 2015

Advanced Proteome Therapeutics’ lead compound inhibits metastasis in breast cancer tumor model


View PDF

April 27, 2015

APC reports successful fusion protein initiative which retards tumor growth in an animal model


View PDF

April 13, 2015

Advanced Proteome Therapeutics announces new patent


View PDF

April 7, 2015

Advanced Proteome Therapeutics announces promising results of triple combination immunotherapy tests


View PDF

March 30, 2015

Advanced Proteome Therapeutics appoints Dr. David Webb to its Corporate Advisory Board


View PDF

March 23, 2015

Advanced Proteome Therapeutics provides corporate update on multiple activities.


View PDF

January 29, 2015

In an Exclusive Interview, the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company’s Technology and R&D Strategy

View PDF

November 12, 2014

Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy

View PDF

September 11, 2014

APC Announces Positive Results in Combination Cancer Immunotherapy.

View PDF

August 12, 2014

Advanced Proteome Therapeutics Expands Anticancer Studies Based on Strong Initial Results

View PDF

July 24, 2014

Advanced Proteome Announces Results of Annual General Meeting, Enters Into Investor Relations Agreement

View PDF

June 10, 2014

Advanced Proteome Adopts Advanced Notice Policy

View PDF

May 22, 2014

Update on Advanced Proteome Therapeutics’ Anticancer Program

View PDF

March 5, 2014

Advanced Proteome Therapeutics Reports Impressive Anticancer Activity

View PDF

January 28, 2014

Advanced Proteome Therapeutics Further Updates Ongoing Activities

View PDF

In the News

Advanced Proteome Therapeutics will provide the latest stories as the media reports our progress, as well as other articles of interest about our technology and industry.

CEOCFO Magazine

Advanced Proteome Therapeutics Corp is focused on developing a Protein Therapeutic that is Targeted and Combines Multiple Anti-Cancer Therapies for Greater Potency, Higher Specificity and Less Toxicity than Individual Therapies

View PDF
Disclaimer

This website contains historical and forward-looking statements. The forward-looking statements involve risks and uncertainties. Forward looking statements appearing on this website in this presentation represent management's current estimates at the time they were posted and these may change significantly as new information comes to hand. The information contained in this website has been obtained by Advanced Proteome Therapeutics Corporation. from its own records and from other sources believed to be reliable, however no representation or warranty is made as to its accuracy or completeness. Reference should be made to the Company's most recent Annual Report filed with Canadian securities regulatory authorities (and available at www.sedar.com) for a description of the major risk factors.

Advanced Proteome Therapeutics Corporation.

Suite 113
650 Albany Street
Boston, Massachusetts
02118 USA

T 617-638-0340
F 617-638-0341
www.advancedproteome.com
akrantz@advancedproteome.com